MX2023007467A - Derivados de indol utiles en el tratamiento de afecciones asociadas con cgas. - Google Patents

Derivados de indol utiles en el tratamiento de afecciones asociadas con cgas.

Info

Publication number
MX2023007467A
MX2023007467A MX2023007467A MX2023007467A MX2023007467A MX 2023007467 A MX2023007467 A MX 2023007467A MX 2023007467 A MX2023007467 A MX 2023007467A MX 2023007467 A MX2023007467 A MX 2023007467A MX 2023007467 A MX2023007467 A MX 2023007467A
Authority
MX
Mexico
Prior art keywords
cgas
conditions associated
treating conditions
indole derivatives
derivatives useful
Prior art date
Application number
MX2023007467A
Other languages
English (en)
Inventor
Richard Heng
David Carcache
Carsten Spanka
Oliver Simic
Florian Gruber
Danilo Guerini
Martin Gunzenhauser
Francesca Perruccio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023007467A publication Critical patent/MX2023007467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

La presente revelación se refiere a un compuesto de Formula (I): (ver Fórmula) (I), o a una sal, hidrato, solvato, estereoisómero o tautómero del mismo farmacéuticamente aceptable, donde R1 hasta R8 son como se los define en este documento, así como también a los métodos para hacerlos y usarlos.
MX2023007467A 2020-12-22 2021-12-20 Derivados de indol utiles en el tratamiento de afecciones asociadas con cgas. MX2023007467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128949P 2020-12-22 2020-12-22
PCT/IB2021/062029 WO2022137085A1 (en) 2020-12-22 2021-12-20 Indole derivatives useful in treating conditions associated with cgas

Publications (1)

Publication Number Publication Date
MX2023007467A true MX2023007467A (es) 2023-07-04

Family

ID=79164465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007467A MX2023007467A (es) 2020-12-22 2021-12-20 Derivados de indol utiles en el tratamiento de afecciones asociadas con cgas.

Country Status (19)

Country Link
US (1) US20230085472A1 (es)
EP (1) EP4267564A1 (es)
JP (1) JP2024502258A (es)
KR (1) KR20230124665A (es)
CN (1) CN116635382A (es)
AR (1) AR124443A1 (es)
AU (1) AU2021404953A1 (es)
CA (1) CA3202212A1 (es)
CL (1) CL2023001859A1 (es)
CO (1) CO2023007954A2 (es)
CR (1) CR20230282A (es)
DO (1) DOP2023000129A (es)
EC (1) ECSP23045506A (es)
IL (1) IL303913A (es)
MX (1) MX2023007467A (es)
PE (1) PE20240229A1 (es)
TW (1) TW202241873A (es)
UY (1) UY39579A (es)
WO (1) WO2022137085A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230391786A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company cGAS INHIBITORS
WO2024083773A1 (en) 2022-10-18 2024-04-25 Glaxosmithkline Intellectual Property Development Limited Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065860A1 (es) * 2007-03-29 2009-07-08 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
SG11201704770YA (en) 2014-12-22 2017-07-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
BR112020016008A2 (pt) * 2018-02-05 2020-12-15 The Rockefeller University Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica

Also Published As

Publication number Publication date
WO2022137085A1 (en) 2022-06-30
DOP2023000129A (es) 2023-07-16
PE20240229A1 (es) 2024-02-16
AU2021404953A1 (en) 2023-06-22
IL303913A (en) 2023-08-01
EP4267564A1 (en) 2023-11-01
JP2024502258A (ja) 2024-01-18
UY39579A (es) 2022-07-29
CN116635382A (zh) 2023-08-22
CL2023001859A1 (es) 2024-02-09
AR124443A1 (es) 2023-03-29
CA3202212A1 (en) 2022-06-30
KR20230124665A (ko) 2023-08-25
ECSP23045506A (es) 2023-07-31
TW202241873A (zh) 2022-11-01
US20230085472A1 (en) 2023-03-16
CR20230282A (es) 2023-07-12
AU2021404953A9 (en) 2024-02-08
CO2023007954A2 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
MX2023007467A (es) Derivados de indol utiles en el tratamiento de afecciones asociadas con cgas.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
JOP20220101A1 (ar) مثبطات صغيرة الجزئ لطافر G12C لبروتين ساركوما جرذان Kirsten (KRAS)
TW200517393A (en) Processes for the preparation of benzoimidazole derivatives
MX2021009763A (es) Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
MX2021001690A (es) Indoles sustituidos y metodos de uso de los mismos.
MX2021009764A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
DE60218194D1 (de) Verwendung von indol- und indolin-derivaten bei der behandlung von adipositas oder zur reduzierung der nahrungsaufnahme
HK1138265A1 (en) Materials and methods for treating coagulation disorders
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
MX2007004910A (es) Nuevos derivados de indol o benzimidazol.
BR112022012273A2 (pt) Composto, pirrolo[3,2-c]piridina, pirrolo[3,2-c]piridazina, indol, método para suprimir a expressão de oncogene em uma célula e método para tratar um paciente com leucemia
TN2021000025A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MX2021012105A (es) Compuestos de pirrol.
AU2021308209A8 (en) Isoquinoline compounds and their use in treating ahr imbalance
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
EA200600570A1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht
MY156955A (en) Antifungal agents
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2021009206A (es) Terapias contra el cancer.
AU2022350571A1 (en) Fgfr inhibitors and methods of use thereof
CR20230193A (es) Derivados de pirazol como inhibidores de la ret-cinasa